期刊文献+

无糖基化修饰GLP-1-Fc(N126A)在酵母中的表达、纯化 被引量:1

Expression and Purification of Non-glycosylated Glp-1-Fc(N126A)Fusion Protein in Yeast Expression System
下载PDF
导出
摘要 胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)是一种肠促胰岛素激素,具有很好的综合降糖效果,但其在血浆中的半衰期只有短暂几分钟,限制了GLP-1在临床方面的应用.为延长GLP-1的半衰期,合成了GLP-1-Fc融合基因,将N-糖基化作用的受体天冬酰胺突变为丙氨酸,构建了无糖基化修饰的GLP-1-Fc(N126A)融合表达载体,利用酵母表达系统成功表达了GLP-1-Fc(N126A)融合蛋白,并利用r Protein A获得了高纯度融合蛋白. Glucagon-like peptide-1(GLP-1) is a kind of ducdenin, which has good and comprehensive hypoglycemic effect. The GLP-1 was easy to be degraded in plasma. To prolong the half-life of GLP-1, the GLP-1-Fc(N126A) was constructed through mutant N-glycosylation asparagine receptor into alanine. The GLP-1-Fc(N126A) fusion protein was obtained by yest expression system, and was purified by rPro-teinA.
作者 乔晓芳 王春艳 顾宝华 田庆南 QIAO Xiaofang WANG Chunyan GU Baohua TIAN Qingnan(Department of Pharmacy, Zhengzhou University, Zhengzhou 450001, China Center of Anyang High- Tech Zone Food and Drug Administration, Anyang 455000, China School of Life Science, Zhengzhou University, Zhengzhou 450001, China)
出处 《郑州大学学报(理学版)》 CAS 北大核心 2016年第4期86-89,共4页 Journal of Zhengzhou University:Natural Science Edition
基金 国家自然科学基金青年科学基金资助项目(31601867) 中国博士后基金特别资助项目(2016T90674)
关键词 胰高血糖素样肽-1 FC融合蛋白 酵母表达 glucagon-like peptide-1 (GLP-1) Fc fusion protein yeast expression
  • 相关文献

参考文献1

二级参考文献23

  • 1侯建华,王翠艳,方园园,杨少辉,薄涛,杨立泉,于雷,李明刚.治疗糖尿病的短肽药物GLP-1在毕赤酵母中的分泌表达[J].生物学通报,2006,41(4):44-47. 被引量:1
  • 2马义,周天鸿.胰高血糖素样肽1的研究及应用进展[J].中国组织工程研究与临床康复,2007,11(29):5806-5809. 被引量:10
  • 3Van Delft J,Uttenthal L O.Identification of amidated forms of GLP-1in rat tissues using a highly sensitive radioimmunoassay[J].Regulatory Peptides,1997,70:191-198.
  • 4Ovalle F.Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes[J].Clin Ther,2011,3(4):393-407.
  • 5Borkiewicz P,Pawlak M,Mackowiak P.The results of prolonged action of GLP-1 on some metabolic parameters[J].Folia Biologica (Krakow),2011,59(1-2):13-17.
  • 6Dharmalingam M,Sriram U,Baruah MP Liraglutide:A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2diabetes mellitus[J].Indian J Endocrinol Metab,2011,15 (1):9-17.
  • 7Mentlein R.Dipeptidyl-peptidase Ⅳ (CD26)-role in the inactiveation of regulatory peptides[J].Regulatory Peptides,1999,85 (1):9-24.
  • 8Doyle M E,Greig N H,Holloway H W,et al.Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent[J].Endocrinology,2001,142(10):4462-4468.
  • 9Green B D,Mooney M H,Gault V A,et al.N-terminal His7-modification of glucagon-like peptide-1 (7-36) amide generates dipeptidyl peptidase Ⅳ-stable analogues with potent antihyperglycaemic activity[J].Journal of Endocrinology,2004,180:379-388.
  • 10Juhl C B,Hollingdal M,Sturis J,et al.Bedtime administration of NN2211,a long-acting GLP-1 derivative,substantially reduces fasting and postprandial glycemia in Type 2 diabetes[J].Diabetes,2002,51:424-429.

共引文献1

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部